TruthArchive.ai - Related Video Feed

I found something interesting for Elon and the Doge team regarding Medicare. In 2022, Medicare filled 85,000 prescriptions for Perfinidone at $8,000 each, totaling $680 million. At my cost-plus pharmacy, the same prescription is only $200. Filling all 85,000 prescriptions with me would only cost $17 million. Medicare is overpaying by $663 million annually because Pharmacy Benefits Managers (PBMs) get a percentage of the cost, incentivizing them to inflate prices. The easy solution is to cancel the PBM contracts and use actual costs. If you want to check if PBMs have been raising the cost of your medications, go to forestparkpharmacy.com and check our price to see how much you could save.

The speaker's administration will implement "most favored nations" drug pricing, ensuring Americans pay the lowest price for drugs compared to other developed countries. Some prescription drug prices will be reduced almost immediately by 50% to 90%. Big Pharma must voluntarily comply or the federal government will ensure equal pricing. To accelerate price reductions, the administration will cut out the middlemen to facilitate direct drug sales to American citizens at the most favored nation price. The speaker believes the middlemen are worse than drug companies because they don't make a product but make a fortune.

A businessman told the speaker that the same fat shot drug cost him $88 in London, but $1,300 in New York. He was stunned that the identical pill, made in the same plant by the same company, had such different prices. The speaker discussed this with drug company representatives. They argued for about half an hour, but ultimately the representative admitted there was no justification for the price difference.

The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the current system was fair, even though the reasons why were not widely understood.

Chemotherapy drugs are prescribed by doctors because they profit directly from them. Doctors buy it for $5,000, sell it for $12,000 to patients, insurance pays $9,000, and doctors keep the $4,000 difference. Chemotherapy's success rate is only 3%, yet it's used for profit. The pharmaceutical industry controls us, diverting funds from breast cancer events to drugs and surgery, neglecting other research like nutrition, homeopathy, acupuncture, and naturopathy.

The administration will secure "most favored nations" drug pricing, meaning Americans will pay the lowest price for drugs paid in other developed countries. Some prescription drug prices will be reduced almost immediately by 50 to 90%. Big Pharma will either abide by this principle voluntarily, or the federal government will ensure Americans pay the same price as other countries. To accelerate price reductions, the administration will cut out the middlemen and facilitate the direct sale of drugs at the most favored nation price directly to American citizens. The middlemen are considered worse than the drug companies because they don't make a product but make a fortune.

The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the existing system was fair, even though the reasons why were not well understood. The speaker claims to have figured out the reasons behind this.

Medicare overspent on tetrabenazine prescriptions in 2022. They spent $141,000,000 across 54,000 prescriptions, averaging $2,600 per prescription. The actual cost of the medication is $75. Thus, $130.7 million was wasted. This is the twentieth drug highlighted where Medicare overpays, bringing the total waste across these drugs to $10.8 billion. A solution would be to eliminate the middleman and revert prices to realistic levels. Forestparkpharmacy.com offers a price checker to demonstrate potential savings.

A businessman told the speaker that the same fat shot drug cost him $88 in London but $1,300 in New York. The drugs were identical, made in the same plant by the same company. The speaker discussed this with a representative from the drug companies, who admitted there was no justification for the price difference.

Therapeutic drugs are the only drugs doctors profit directly from. Chemotherapy is used because it's profitable, not effective. The pharmaceutical industry controls us. Funds raised for breast cancer don't support alternative treatments, only drugs and surgery that don't work.

Politicians have long promised to eliminate the discrepancy between drug prices in the U.S. and Europe. This was a key issue for Bernie Sanders, but previous leaders haven't acted on it. Politicians make these promises knowing they likely won't have to fulfill them. The reason is that Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member.

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

Chemo drugs are the only ones doctors profit directly from. They buy it for $5,000, sell it to patients for $12,000, and insurance pays $9,000. Doctors keep $4,000. Chemotherapy is used because it makes money, not because it works (97% failure rate). The pharmaceutical industry controls us. Money raised for breast cancer doesn't go to alternative treatments or research, only drugs and surgery that don't work.

One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

Therapeutic drugs are unique because prescribing doctors receive a direct profit from them. For example, a doctor purchases chemotherapy for $5,000, sells it for $12,000, and after insurance pays $9,000, the doctor keeps the $4,000 difference. This profit motive raises concerns about the efficacy of chemotherapy, which reportedly fails 97% of the time. If a car manufacturer had such a failure rate, they wouldn't survive. Additionally, fundraising for breast cancer often does not support alternative treatments like nutritional research or acupuncture; instead, it primarily funds drugs and surgeries that are ineffective.

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker highlights the significant price difference, noting one person paid a small amount for the same shot in the UK. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world, according to the speaker, who questions the reason for this disparity.

I've identified wasteful spending in Medicare, specifically with generic Cialis, or Tadalafil. In 2022, Medicare spent $237 million on this drug, averaging $481 per prescription across 492,000 prescriptions. However, at my pharmacy, the same prescription costs only $14 without insurance. That means it would only cost $7 million to cover the entire country at my pharmacy's pricing. The overcharge of $230 million for just this one drug is due to pharmacy benefits managers (PBMs). PBMs manage all pharmacy-related aspects for Medicare, deciding coverage, copays, government costs, and pharmacy payments. They've essentially decided on a 3000% markup. It's time to fire the PBMs and bring prices back to reality. To check the markups on your prescriptions, visit forestparkpharmacy.com and use our price checker.

Politicians have long promised to address the discrepancy between drug prices in the U.S. and Europe. This issue was central to Bernie Sanders' presidential campaigns. However, these promises were never fulfilled because Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every member of Congress, the Senate, and the Supreme Court.

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker stated that an individual in the UK paid a small amount for their shot, contrasting sharply with the $500 cost in the US. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world. The speaker questions the reason for this disparity.

We're continuing our investigation into Medicare overspending, and today we found Aripiprazole. In 2022, Medicare spent $1.5 billion on this drug, with 7.2 million prescriptions at an average cost of $208. However, at my pharmacy, without insurance, the same medication costs only $12. Filling all those prescriptions at my pharmacy would only cost $86 million. That means over $1.4 billion was wasted due to pharmacy benefits managers (PBMs) using inflated prices and directing patients to pharmacies they own. The solution is simple: cancel the PBM contracts, eliminate the made-up prices, and get back to reality. To see how much you've been overcharged, visit forestparkpharmacy.com and use our price checker to see your potential savings.

Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.